Tanja Gruber

Tanja A. Gruber, MD, PhD

Assistant Member, St. Jude Faculty

Departments

Oncology

Divisions

Leukemia / Lymphoma

Contact Information

Tanja Gruber, MD, PhD
Leukemia / Lymphoma
MS 342, Room D4026F
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: tanja.gruber@stjude.org
Phone: (901) 595-2252
FAX: (901) 595-5947

Education

BS - Biology, University of Washington, Seattle, Washington (1995)
BS - Biochemistry, University of Washington, Seattle, Washington (1995)
PhD - Immunology, University of Southern California, Los Angeles, California (2001)
MD - Medicine, University of Southern California, Los Angeles, California (2003)


Research Interests

Research in my laboratory focuses on two subtypes of high risk leukemia: MLL-rearranged (MLL-r) infantile acute lymphoblastic leukemia (ALL) and acute megakaryoblastic leukemia in non-Down syndrome patients (non-DS AMKL). These malignancies are driven by recurring chromosomal abnormalities that create the novel fusion genes MLL-AF4 (in MLL-r infant ALL) and CBFA2T3-GLIS2 (in non-DS AMKL). Our focus is on the mechanism whereby these fusions contribute to leukemogenesis with the long term goal of defining pathways and/or proteins to target therapeutically.


Selected Publications

Gruber TA, Gedman AL, Zhang J, Koss CS, Marada S, Ta H, Chen S-C, Su X, Ogden SK, Dang J, Gupta V, Andersson A, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ganti R, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau S, Ravandi-Kashani F, Kantarjian H, Nimer SD, Doehner K, Doehner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih L-Y, Liang D-C, Rubnitz J, Pui C-H, Mardis ER, Wilson RK, Downing JR. Transcriptome sequence analysis of pediatric acute megakaryoblastic leukemia identifies an inv(16)(p13.3;q24.3)-encoded CBFA2T3-GLIS2 fusion protein as a recurrent lesion in 30% of cases. Cancer Cell 22: 683–697, 2012.

Gruber TA, Chang MS, Sposto R, Müschen M. Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia. Cancer Research 70(19):7411-7420, 2010.

Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim Y, Hofmann W, Li A, Storlazzi C, Jack H, Groffen J, Martinelli G, Heisterkamp N, Jumaa H, Muschen M. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med 206:1739-1753, 2009.

Gruber TA, Shah AJ, Hernandez M, Abdel-Azim H, Crooks GM, Kapoor N, Gupta S, McKnight S, Schofield D, White D, Kohn DB. Clinical and genetic heterogeneity in Omenn Syndrome and severe combined immune deficiency. Pediatr Transplant 13:244-250, 2009.

Gruber TA, Skelton DC, Kohn DB. Recombinant murine interleukin-12 elicits potent antileukemic immune responses in a murine model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Gene Ther 12:818-824, 2005.

Gruber TA, Skelton DC, Kohn DB. Requirement for natural killer cells in CD40 ligand mediated rejection of Philadelphia chromosome positive acute lymphoblastic leukemia cells. J Immunol 168:73-80, 2002.

Stripecke R, Skelton DC, Gruber T, Afar D, Pattengale PK, Witte O, Kohn DB. Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 9:2049-2062, 1998.


Last update: November 2012